Richard Frenette

This inventor holds 27 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Merck Frosst Canada, Inc., Merck Frosst Canada & Co., Bhi Limited Partnership. Active years: 1987-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Frenette. Retrieved from https://idiyas.com/inventor/richard-frenette

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 2)

% Patents Active = 77.8

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 4.5

ph-index = 10

Forward Citations = 262(Granted Patents)

Location History:

Lavel, CA (1994)
Vimont, CA (1998)
Quebec, CA (1991 - 2001)
Laval, CA (1987 - 2015)

Company Filing History:

18 out of 212

Merck Frosst Canada, Inc.

patents

7 out of 80

Merck Frosst Canada & Co.

patents

1 out of 5

Bhi Limited Partnership

Merck Sharp + Dohme Corp.

patents

where one patent can have more than one assignee

Years Active: 1987-2015

Loading Chart...

Areas of Expertise:

PDE4 Inhibitors

Leukotriene Antagonists

Phenylquinoline

Chromen-2-one

Heterosubstituted Pyridine

Bicyclic Indoles

Tri-aryl-substituted-ethane

Cyclooxygenase Inhibitors

Propanedisulfonic Acid

Diphenyl Cycloalkanes

Stereoselective Synthesis

Azaarylmethoxy Indoles

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9051248 - Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (2015-06-09),

2. 7960409 - Pharmaceutical phenylquinoline and chromen-2-one triazole compounds (2011-06-14),

3. 7943649 - 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors (2011-05-17),

4. 7629467 - Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use (2009-12-08),

5. 7442716 - 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors (2008-10-28),

6. 6841564 - Tri-aryl-substituted-ethane PDE4 inhibitors (2005-01-11),

7. 6639077 - Tri-aryl-substituted-ethane PDE4 inhibitors (2003-10-28),

8. 6399636 - Tri-aryl-substituted-ethane PDE4 inhibitors (2002-06-04),

9. 6316472 - Heterosubstituted pyridine derivatives as PDE 4 inhibitors (2001-11-13),

10. 6204275 - PDE IV inhibiting compounds, compositions and methods of treatment (2001-03-20),

11. 6200993 - Heterosubstituted pyridine derivatives as PDE4 inhibitors (2001-03-13),

12. 6180650 - Heterosubstituted pyridine derivatives as PDE 4 inhibitors (2001-01-30),

13. 5817700 - Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors (1998-10-06),

14. 5389650 - (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis (1995-02-14),

15. 5380850 - (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of (1995-01-10),

Title: The Innovative Journey of Richard Frenette in Patent Development

Introduction

Richard Frenette, based in Laval, Canada, is a prolific inventor with an impressive portfolio of 27 patents. His contributions to the field of pharmaceutical science demonstrate a commitment to advancing medical treatments and addressing various health conditions through innovative compounds and methods.

Latest Patents

Among Frenette's latest innovations are significant advancements related to the delivery of 1,3-propanedisulfonic acid (1,3PDS). This invention outlines methods, compounds, and compositions designed to effectively deliver 1,3PDS in subjects, particularly humans. It explores compounds capable of generating 1,3PDS either in vitro or in vivo, which may include sulfonate ester prodrugs and Gemini dimmers. These innovations aim to prevent or treat diseases and conditions associated with 1,3PDS.

Additionally, Frenette's invention regarding pharmaceutical phenylquinoline and chromen-2-one triazole compounds presents compounds that inhibit leukotriene biosynthesis. These compounds hold promise as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents, paving the way for new therapeutic approaches.

Career Highlights

Richard Frenette has built a noteworthy career working with prominent companies, including Merck Frosst Canada, Inc. and Merck Frosst Canada & Co. His expertise and innovative thinking have made substantial impacts in the pharmaceutical industry, contributing to the development of medications that improve patients' lives.

Collaborations

Throughout his career, Frenette has collaborated with esteemed colleagues such as Yves Ducharme and Richard W. Friesen. These partnerships have fostered an environment of innovation and progress, allowing them to tackle complex challenges in drug development and to bring valuable inventions to fruition.

Conclusion

With a wealth of experience and a passion for innovation, Richard Frenette continues to be a significant figure in the realm of pharmaceutical development. His patents not only reflect his creativity and ingenuity but also his dedication to enhancing medical treatments for various health conditions, marking him as an invaluable asset to the world of science and technology.

Profile summary based on public USPTO records.